CD274 and neoplasm: Based on this, blocking the PD‐1/PD‐L1 signaling pathway with immune checkpoint inhibitors (ICIs) restores immune surveillance and augments T‐cell‐mediated antitumor responses, which leads to the development of ICIs for tumor treatment.